Acquired or inherited defects in DNA repair pathways can be effectively utilized in the therapy; for instance, CRC patients bearing deficiency in RAD51C or CHEK2 genes, belonging to HR pathway, benefited from the treatment with olaparib [149]. This evidence concerns the gene RAD51C and colorectal carcinoma.